Harbin Yerui Pharmaceutical

Harbin Yerui Pharmaceutical is a key subsidiary and manufacturing arm of Harbin Gloria Pharmaceuticals (also known as Yuheng Pharmaceutical), a leading Chinese pharmaceutical group. Based in Harbin, the company specializes in the development and production of a wide range of therapeutic products, including cardiovascular drugs, orthopedic treatments, and anti-infectives. Its commercial portfolio features prominent products such as Sodium Creatine Phosphate for Injection and Ginkgo Damo Injection. Through its affiliation with the Gloria group and Gloria Biosciences, Harbin Yerui is involved in the commercialization and manufacturing of innovative biologics, most notably the PD-1 inhibitor zimberelimab. The company operates large-scale, GMP-certified manufacturing facilities and serves as a critical component of the group's integrated R&D and sales operations.